– USA, NY – Truveris, the leading provider of pharmacy benefits solutions, today announced the appointment of health care industry executive Matthew J. Simas to its Board of Directors.

Mr. Simas is a seasoned leader and well-respected investor with a successful track record in health care technology, strategy and M&A. Previous roles include Executive Vice President, Chief of Markets for MedImpact Healthcare Systems, Inc., the largest independently held pharmacy benefit management (PBM) company, and Operating Partner with SilverStream Captial, LLC, based in San Diego. During his seven year tenure as an operationally active board member for MedImpact, he facilitated significant revenue growth and a number of key transactions.

He also served as President, COO and Board member of HealthyCircles, and General Manager at IMS Health, a global health care data company.

“Matthew’s decades of experience in our industry – spanning data and information management and investment strategy – make him an asset to our Board of Directors,” said Marcia Radosevich, a Truveris Director and Board Member. “As we continue to grow, his insights and expertise will prove invaluable.”

About Truveris

Truveris is on a mission to keep Americans healthy by decreasing prescription drug spend across the pharmacy value chain. Our proprietary Software-As-A-Service platforms empower clients – from the individual patient to pharmacy benefits stakeholders – with the tools to more effectively and efficiently manage the complexity and rising costs of medications today. Truveris is supported by Canaan Partners, New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round Capital.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>

Comments are closed.